← Back
Data updated: Jun 28, 2026
DUCHESNAY
Specialty Pharmaceuticals
DUCHESNAY is a specialty pharmaceutical company with 3 FDA-approved products.
2013
Since
3
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
3 Small Molecules
DUCHESNAY's Key Drugs
DUCHESNAY's core commercial portfolio centers on OSPHENA, DICLEGIS, BONJESTA — its most strategically important drugs approved in the last 15 years.
DUCHESNAY's Recent FDA Approvals
New NDA/BLA approvals for DUCHESNAY over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
DUCHESNAY's Therapeutic Areas
Disease areas where DUCHESNAY has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
DUCHESNAY Pipeline Snapshot
Active clinical trials for DUCHESNAY across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • OSPHENA leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling